Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study

BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of polymyxin b (PMXB) including therapy receiving cases with colistin receiving cases on culture-proven carbapenem-resistant Gram-negative infections (CPCRGNI). METHOD: This study was performed at a...

Full description

Saved in:
Bibliographic Details
Main Authors: Merve Mert Vahabi, Deniz Akyol, Olcay Buse Kenanoğlu, Gamze Şanlıdağ, Şevket Yeniyol, Deniz Dağ, Cansu Bulut Avşar, Ayşe Önal, Şükrü Dirik, Meltem Tüğdür, Uğur Önal, Gökhan Vatansever, Seichan Ketentzi, Arda Kaya, Oğuzhan Acet, Nazlıhan Yalçın, Buğra Özkara, Hilal Sipahi, Bilgin Arda, Oğuz Reşat Sipahi
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Journal of Global Antimicrobial Resistance
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221371652400184X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850040819649609728
author Merve Mert Vahabi
Deniz Akyol
Olcay Buse Kenanoğlu
Gamze Şanlıdağ
Şevket Yeniyol
Deniz Dağ
Cansu Bulut Avşar
Ayşe Önal
Şükrü Dirik
Meltem Tüğdür
Uğur Önal
Gökhan Vatansever
Seichan Ketentzi
Arda Kaya
Oğuzhan Acet
Nazlıhan Yalçın
Buğra Özkara
Hilal Sipahi
Bilgin Arda
Oğuz Reşat Sipahi
author_facet Merve Mert Vahabi
Deniz Akyol
Olcay Buse Kenanoğlu
Gamze Şanlıdağ
Şevket Yeniyol
Deniz Dağ
Cansu Bulut Avşar
Ayşe Önal
Şükrü Dirik
Meltem Tüğdür
Uğur Önal
Gökhan Vatansever
Seichan Ketentzi
Arda Kaya
Oğuzhan Acet
Nazlıhan Yalçın
Buğra Özkara
Hilal Sipahi
Bilgin Arda
Oğuz Reşat Sipahi
author_sort Merve Mert Vahabi
collection DOAJ
description BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of polymyxin b (PMXB) including therapy receiving cases with colistin receiving cases on culture-proven carbapenem-resistant Gram-negative infections (CPCRGNI). METHOD: This study was performed at a 1800+ bedded tertiary-care hospital. Adult patients with culture proven CRCRGNI (bacteremia, pneumonia etc.) treated with PMXB or colistin including regimens between August 2016 and October 2023 were included.Matching was performed as one PMXB matched to minimum 1 or 2 colistin whenever possible according to the clinical sample infecting strain was yielded (pneumonia vs. pneumonia etc.) RESULTS: A total of 210 patients(72 (36,00%)female, aged 60,26±17,44),79 cases in PMXB group and 131 cases in colistin group diagnosed with CRCRGNI.Sixty strains had colistin susceptibility data and 56(93.3%) strains were sensitive to colistin.OMM in overall cohorts (56.96% in PMXB 58,01% in colistin p:0.881), overall acute kidney injury, overall microbiological success, and overall clinical success at the end of therapy did not differ significantly(Table). OMM in the overall UTI(3/6 50,0% vs 9/12 75,0% p0.288) and pneumonia subgroups(23/35 65,71% vs 46/70 65,71% p:1) were also similar. Both treatment group OMM were similar in Acinetobacter and Klebsiella subgroups, but significantly lower with PMXB in Pseudomonas subgroup (Table).OMM was also similar within known colistin-sensitive cases(34/56 -60,71%) vs others(77/154- 50,0%)(p:0.168). Interestingly, OMM in overall UTI(OMM 3/6-50% vs 7/12-58.3%) was not significantly different, but in favor of PMXB. CONCLUSIONS: PMXB including therapy resulted nonsignificntly less OMM than colistin cohort and significantly less OMM in Pseudomonas subgroup. Nephrotoxicity was nonsignificantly less in PMXB cohort.
format Article
id doaj-art-a3e4363686ee431d99ced4d29836f787
institution DOAJ
issn 2213-7165
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Journal of Global Antimicrobial Resistance
spelling doaj-art-a3e4363686ee431d99ced4d29836f7872025-08-20T02:55:57ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-0139310.1016/j.jgar.2024.10.007Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort StudyMerve Mert Vahabi0Deniz Akyol1Olcay Buse Kenanoğlu2Gamze Şanlıdağ3Şevket Yeniyol4Deniz Dağ5Cansu Bulut Avşar6Ayşe Önal7Şükrü Dirik8Meltem Tüğdür9Uğur Önal10Gökhan Vatansever11Seichan Ketentzi12Arda Kaya13Oğuzhan Acet14Nazlıhan Yalçın15Buğra Özkara16Hilal Sipahi17Bilgin Arda18Oğuz Reşat Sipahi19Ege University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeKanuni Sultan Süleyman Research and Training Hospital, İstanbul TürkiyEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeYüksek İhtisas Research and Training Hospital, Bursa, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeUludağ University, Faculty of Medicine Infectious Diseases and Clinical Microbiology, Bursa, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeBornova Health Directorate, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeBACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of polymyxin b (PMXB) including therapy receiving cases with colistin receiving cases on culture-proven carbapenem-resistant Gram-negative infections (CPCRGNI). METHOD: This study was performed at a 1800+ bedded tertiary-care hospital. Adult patients with culture proven CRCRGNI (bacteremia, pneumonia etc.) treated with PMXB or colistin including regimens between August 2016 and October 2023 were included.Matching was performed as one PMXB matched to minimum 1 or 2 colistin whenever possible according to the clinical sample infecting strain was yielded (pneumonia vs. pneumonia etc.) RESULTS: A total of 210 patients(72 (36,00%)female, aged 60,26±17,44),79 cases in PMXB group and 131 cases in colistin group diagnosed with CRCRGNI.Sixty strains had colistin susceptibility data and 56(93.3%) strains were sensitive to colistin.OMM in overall cohorts (56.96% in PMXB 58,01% in colistin p:0.881), overall acute kidney injury, overall microbiological success, and overall clinical success at the end of therapy did not differ significantly(Table). OMM in the overall UTI(3/6 50,0% vs 9/12 75,0% p0.288) and pneumonia subgroups(23/35 65,71% vs 46/70 65,71% p:1) were also similar. Both treatment group OMM were similar in Acinetobacter and Klebsiella subgroups, but significantly lower with PMXB in Pseudomonas subgroup (Table).OMM was also similar within known colistin-sensitive cases(34/56 -60,71%) vs others(77/154- 50,0%)(p:0.168). Interestingly, OMM in overall UTI(OMM 3/6-50% vs 7/12-58.3%) was not significantly different, but in favor of PMXB. CONCLUSIONS: PMXB including therapy resulted nonsignificntly less OMM than colistin cohort and significantly less OMM in Pseudomonas subgroup. Nephrotoxicity was nonsignificantly less in PMXB cohort.http://www.sciencedirect.com/science/article/pii/S221371652400184Xpolymyxinmultidrug resistancecarbapenem resistance
spellingShingle Merve Mert Vahabi
Deniz Akyol
Olcay Buse Kenanoğlu
Gamze Şanlıdağ
Şevket Yeniyol
Deniz Dağ
Cansu Bulut Avşar
Ayşe Önal
Şükrü Dirik
Meltem Tüğdür
Uğur Önal
Gökhan Vatansever
Seichan Ketentzi
Arda Kaya
Oğuzhan Acet
Nazlıhan Yalçın
Buğra Özkara
Hilal Sipahi
Bilgin Arda
Oğuz Reşat Sipahi
Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
Journal of Global Antimicrobial Resistance
polymyxin
multidrug resistance
carbapenem resistance
title Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
title_full Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
title_fullStr Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
title_full_unstemmed Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
title_short Polymyxin Including Therapy Versus Colistin Including Therapy In The Therapy Of Carbapenem-Resistant Gram-Negative Infections: A Retrospective Matched Cohort Study
title_sort polymyxin including therapy versus colistin including therapy in the therapy of carbapenem resistant gram negative infections a retrospective matched cohort study
topic polymyxin
multidrug resistance
carbapenem resistance
url http://www.sciencedirect.com/science/article/pii/S221371652400184X
work_keys_str_mv AT mervemertvahabi polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT denizakyol polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT olcaybusekenanoglu polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT gamzesanlıdag polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT sevketyeniyol polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT denizdag polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT cansubulutavsar polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT ayseonal polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT sukrudirik polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT meltemtugdur polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT uguronal polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT gokhanvatansever polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT seichanketentzi polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT ardakaya polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT oguzhanacet polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT nazlıhanyalcın polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT bugraozkara polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT hilalsipahi polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT bilginarda polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy
AT oguzresatsipahi polymyxinincludingtherapyversuscolistinincludingtherapyinthetherapyofcarbapenemresistantgramnegativeinfectionsaretrospectivematchedcohortstudy